Article
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
The Journal of clinical investigation - 1 Oct 2006
Engelman Jeffrey A, Mukohara Toru, Zejnullahu Kreshnik, Lifshits Eugene, Borrás Ana M, Gale Christopher-Michael, Naumov George N, Yeap Beow Y, Jarrell Emily, Sun Jason, Tracy Sean, Zhao Xiaojun, Heymach John V, Johnson Bruce E, Cantley Lewis C, Jänne Pasi A
Abstract excerpt
EGFR is frequently mutated and amplified in lung adenocarcinomas sensitive to EGFR inhibitors gefitinib and erlotinib. A secondary mutation, T790M, has been associated with acquired resistance but has not been shown to be sufficient to render EGFR mutant/amplified lung cancers resistant to EGFR inhibitors. We created a model for studying acquired resistance to gefitinib by prolonged exposure of a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.